Cristian C Aragón1,2, Iván Posso-Osorio1,2, Germán Puerta2, Juan-David González1, Juan-Camilo Naranjo1,2, Alex Echeverri2, Eliana Ortíz3, Ivana Nieto-Aristizábal2, María Claudia Barrera1,2, Lady J Ríos-Serna1,2, Gabriel J Tobón4,5. 1. Medical School, Universidad Icesi, Cali, Colombia. 2. GIRAT: Grupo de Investigación en Reumatología, Autoinmunidad y Medicina Traslacional, Fundación Valle Del Lili and Universidad Icesi, Cali, Colombia. 3. Laboratory of Immunology, Fundación Valle Del Lili, Cali, Colombia. 4. GIRAT: Grupo de Investigación en Reumatología, Autoinmunidad y Medicina Traslacional, Fundación Valle Del Lili and Universidad Icesi, Cali, Colombia. gtobon1@yahoo.com. 5. Laboratory of Immunology, Fundación Valle Del Lili, Cali, Colombia. gtobon1@yahoo.com.
Abstract
INTRODUCTION/ OBJECTIVES: Anti-dense fine speckled 70 (DFS70) autoantibodies were reported to be more prevalent in healthy individuals than those with autoimmune diseases such as systemic lupus erythematosus (SLE). We determined anti-DFS70 autoantibody prevalence in a Latin American cohort of patients with SLE and healthy individuals. METHODS: This study included 127 individuals with anti-nuclear antibodies (ANAs; > 1:160) suggesting the presence of anti-DFS70, including 64 patients with SLE and 63 healthy controls. The anti-DFS70 autoantibodies were determined by immunoadsorption using NOVA Lite® HEp-2 Select kit with DAPI. Negative fluorescence after adsorption with the DFS70 antigen indicated anti-DFS70 autoantibody positivity. RESULTS: The presence of anti-DFS70 autoantibodies was confirmed by indirect immunofluorescence in 21 (33.3%) healthy controls and 8 (12.5%) patients with SLE (p = 0.005). Among the anti-DFS70-positive patients with SLE, the most frequent compromise was renal involvement in six cases (75%), 4 patients (37.5%) were positive for anti-Sm, which was the most frequently associated antibody, and one patient (12.5%) was positive for anti-DNA. CONCLUSIONS: Anti-DFS70 autoantibodies might be considered a biomarker to differentiate patients with SLE from ANA-positive individuals without autoimmune diseases. KEY POINTS: • In a Latin American cohort, the anti-DFS70 was higher in individuals without autoimmune diseases compared with that in patients with SLE.• The anti-DFS70 might have utility as a biomarker of exclusion in patients with non-specific clinical signs of AARDs.
INTRODUCTION/ OBJECTIVES:Anti-dense fine speckled 70 (DFS70) autoantibodies were reported to be more prevalent in healthy individuals than those with autoimmune diseases such as systemic lupus erythematosus (SLE). We determined anti-DFS70 autoantibody prevalence in a Latin American cohort of patients with SLE and healthy individuals. METHODS: This study included 127 individuals with anti-nuclear antibodies (ANAs; > 1:160) suggesting the presence of anti-DFS70, including 64 patients with SLE and 63 healthy controls. The anti-DFS70 autoantibodies were determined by immunoadsorption using NOVA Lite® HEp-2 Select kit with DAPI. Negative fluorescence after adsorption with the DFS70 antigen indicated anti-DFS70 autoantibody positivity. RESULTS: The presence of anti-DFS70 autoantibodies was confirmed by indirect immunofluorescence in 21 (33.3%) healthy controls and 8 (12.5%) patients with SLE (p = 0.005). Among the anti-DFS70-positive patients with SLE, the most frequent compromise was renal involvement in six cases (75%), 4 patients (37.5%) were positive for anti-Sm, which was the most frequently associated antibody, and one patient (12.5%) was positive for anti-DNA. CONCLUSIONS: Anti-DFS70 autoantibodies might be considered a biomarker to differentiate patients with SLE from ANA-positive individuals without autoimmune diseases. KEY POINTS: • In a Latin American cohort, the anti-DFS70 was higher in individuals without autoimmune diseases compared with that in patients with SLE.• The anti-DFS70 might have utility as a biomarker of exclusion in patients with non-specific clinical signs of AARDs.
Authors: Henrique A Mariz; Emília I Sato; Silvia H Barbosa; Silvia H Rodrigues; Alessandra Dellavance; Luis E C Andrade Journal: Arthritis Rheum Date: 2011-01
Authors: E M Tan; T E Feltkamp; J S Smolen; B Butcher; R Dawkins; M J Fritzler; T Gordon; J A Hardin; J R Kalden; R G Lahita; R N Maini; J S McDougal; N F Rothfield; R J Smeenk; Y Takasaki; A Wiik; M R Wilson; J A Koziol Journal: Arthritis Rheum Date: 1997-09
Authors: Michelle Petri; Ana-Maria Orbai; Graciela S Alarcón; Caroline Gordon; Joan T Merrill; Paul R Fortin; Ian N Bruce; David Isenberg; Daniel J Wallace; Ola Nived; Gunnar Sturfelt; Rosalind Ramsey-Goldman; Sang-Cheol Bae; John G Hanly; Jorge Sánchez-Guerrero; Ann Clarke; Cynthia Aranow; Susan Manzi; Murray Urowitz; Dafna Gladman; Kenneth Kalunian; Melissa Costner; Victoria P Werth; Asad Zoma; Sasha Bernatsky; Guillermo Ruiz-Irastorza; Munther A Khamashta; Soren Jacobsen; Jill P Buyon; Peter Maddison; Mary Anne Dooley; Ronald F van Vollenhoven; Ellen Ginzler; Thomas Stoll; Christine Peschken; Joseph L Jorizzo; Jeffrey P Callen; S Sam Lim; Barri J Fessler; Murat Inanc; Diane L Kamen; Anisur Rahman; Kristjan Steinsson; Andrew G Franks; Lisa Sigler; Suhail Hameed; Hong Fang; Ngoc Pham; Robin Brey; Michael H Weisman; Gerald McGwin; Laurence S Magder Journal: Arthritis Rheum Date: 2012-08
Authors: Minoru Satoh; Edward K L Chan; Lindsey A Ho; Kathryn M Rose; Christine G Parks; Richard D Cohn; Todd A Jusko; Nigel J Walker; Dori R Germolec; Irene Z Whitt; Patrick W Crockett; Brad A Pauley; Jason Y F Chan; Steven J Ross; Linda S Birnbaum; Darryl C Zeldin; Frederick W Miller Journal: Arthritis Rheum Date: 2012-07
Authors: Michael Mahler; Todd Parker; Carol L Peebles; Luis E Andrade; Andreas Swart; Yvette Carbone; David J Ferguson; Danilo Villalta; Nicola Bizzaro; John G Hanly; Marvin J Fritzler Journal: J Rheumatol Date: 2012-09-01 Impact factor: 4.666